Clinical trial
Impact of Hepatic Impairment on the Pharmacokinetics of Deferasirox.
NCT00432627 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00432627 |
|---|---|
| Title | Impact of Hepatic Impairment on the Pharmacokinetics of Deferasirox. |
| Official title | An Open-label, Single-dose, Parallel-group Study to Assess the Pharmacokinetics of 20 mg/kg Oral Deferasirox in Patients With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hepatic Impairment |
| Intervention type | Drug |
| Interventions | Deferasirox |
| Enrollment | 24 |
| Start date | Dec 1, 2006 |
| Primary completion | Aug 1, 2010 |
| Completion | Aug 1, 2010 |
| First posted | Feb 8, 2007 |
| Last update posted | Dec 9, 2020 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: